Leidos to Invest $10M in University of Pittsburgh for AI Disease Detection

Leidos is investing $10 million in a five-year collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE) to advance the development and application of artificial intelligence (AI) in disease detection and management. This partnership is designed to accelerate the creation of AI-powered tools that can enhance the speed and accuracy of diagnosing conditions such as heart disease and cancer, reduce diagnostic turnaround times, and enable earlier, more effective care.

Drawing on more than 25 years of experience operating the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and two decades of applying AI across healthcare and other critical sectors, Leidos brings significant expertise to the initiative. The University of Pittsburgh will expand CPACE by enhancing its cutting-edge Digital Pathology Research Center, creating a premier hub for digital pathology and AI-driven diagnostics. Together, Leidos and the University aim to drive advancements in digital healthcare technologies, reinforcing Pittsburgh’s leadership in the field while enabling Leidos to develop innovative digital health and diagnostic solutions.

The collaboration is also geared toward global impact, with Leidos aiming to deploy AI-powered digital pathology solutions across both public and private healthcare sectors and support the commercialization of these technologies. Leidos CEO Tom Bell emphasized the broader goals of the initiative, stating that the investment is intended to harness AI’s transformative potential to accelerate disease detection, diagnosis, and treatment for millions of people each year. Additionally, the effort will contribute to training future healthcare specialists and improving access to care for underserved communities, including veterans.